Compare NTWK & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTWK | RNTX |
|---|---|---|
| Founded | 1997 | 2001 |
| Country | United States | United States |
| Employees | N/A | 10 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.7M | 42.9M |
| IPO Year | 1997 | N/A |
| Metric | NTWK | RNTX |
|---|---|---|
| Price | $3.46 | $1.63 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 26.3K | ★ 114.9K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 316.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $73,088,687.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 13.40 | N/A |
| 52 Week Low | $2.26 | $1.02 |
| 52 Week High | $5.75 | $2.22 |
| Indicator | NTWK | RNTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.01 | 68.31 |
| Support Level | $2.89 | $1.08 |
| Resistance Level | $3.70 | $2.18 |
| Average True Range (ATR) | 0.16 | 0.18 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 56.29 | 89.83 |
NETSOL Technologies Inc is an information technology and enterprise software solutions provider to original equipment manufacturers (OEMs), dealerships, and financial institutions to sell, finance, and lease assets. The firm's products include Transcend Retail, Transcend Finance, Transcend Marketplace, Transcend Consultancy, and Transcend AI Labs, catering to its customers in the different stages of how assets are sold, financed, and leased. Its primary sources of revenue are licensing, subscriptions, modification, enhancement, and support of its suite of financial applications offered to businesses in the finance and leasing space, as well as automotive digital retail. The company has three reportable segments: Asia-Pacific, its key revenue-generating market, North America, and Europe.
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.